No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 8113.7x · 10Y median 2041.1x · 82nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:48:08.952Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Lyell Immunopharma, Inc. (LYEL) stock was $8.94 as of Oct 6, 2026, 12:45 PM EDT, down 1.43% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -48.7% · 3-year avg -32.7%/yr · 5-year avg -48.2%/yr
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Biotechnology · South San Francisco, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 10, 2026
35 days away
EPS Estimate
-2.06
Revenue Est.
$4600.00
Last Quarter Results
EPS
$-1.74
vs Estimate
$-1.79
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LYEL | $219.07M | $8.94 | -1.43% | -48.74% | -48.18% | N/A | N/A |
| 2ALEC | $217.34M | $1.96 | -1.63% | -39.91% | -39.17% | N/A | vs LYEL |
| 3KROS | $222.26M | $11.21 | -2.69% | -27.62% | -21.98% | N/A | vs LYEL |
| 4NNNN | $214.85M | $4.89 | +1.35% | -84.84% | N/A | N/A | vs LYEL |
| 5NAGE | $214.64M | $2.69 | +0.56% | -61.15% | -15.72% | -1.06% | vs LYEL |
| 6PRLD | $213.50M | $3.75 | -0.53% | +155.31% | -33.98% | N/A | vs LYEL |
forward FY estimate
N/A
$4000.00
vs Estimate
$3625.00
Consensus Rating
Based on 8 analysts
Average Price Target
$37.88
+323.7% upside
Low
$12.00
Current
$8.94
High
$49.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.11 | $-2.03 | $-1.94 | 2 |
| Quarter ending Dec 2026 | $-2.27 | $-2.13 | $-1.90 | 2 |
| Quarter ending Mar 2027 | $-2.13 | $-2.13 | $-2.13 | 1 |
| Quarter ending Jun 2027 | $-2.16 | $-2.16 | $-2.16 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-7.50 | $-7.24 | $-6.98 | 4 |
| FY 2027 | $-10.28 | $-7.59 | $-5.51 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4600.00 | $4600.00 | $4600.00 | 7 |
| Quarter ending Dec 2026 | $3400.00 | $3400.00 | $3400.00 | 7 |
| Quarter ending Mar 2027 | $6667.00 | $6667.00 | $6667.00 | 3 |
| Quarter ending Jun 2027 | $7000.00 | $7000.00 | $7000.00 | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $11872.00 | $11875.00 | $11877.00 | 8 |
| FY 2027 | $1004.00 | $13167.00 | $26643.00 | 8 |
